AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19404053 — intervention group
Group type: COMPARATOR
Intervention: Open anterior resection
Number of subjects: 153
Study 17658017 — intervention group
Group type: EXPERIMENTAL
Intervention: ON-Q bupivicaine pain pump
Number of subjects: 40
Study 17658017 — intervention group
Group type: COMPARATOR
Intervention: meperidine PCA
Number of subjects: 40
Study 14992883 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg/daily)
Number of subjects: 253
Study 14992883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (80 mg twice daily)
Number of subjects: 253
Study 11843924 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic cream applied to the nose twice daily for 4 weeks
Number of subjects: 103
Study 11843924 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 103
Study 10546408 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (5 ml, equal to 100 mg, x 4/day for 3 days on average)
Number of subjects: 31
Study 10546408 — intervention group
Group type: COMPARATOR
Intervention: Neomycin + bacitracin (5 ml x 4/day for 4 days on average)
Number of subjects: 31
Study 8044619 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation (n = 89)
Number of subjects: 169
Study 8044619 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation (n = 97)
Number of subjects: 169
Study 2903762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine 2.5 mg
Number of subjects: 14
Study 2903762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine 5 mg
Number of subjects: 14
Study 2903762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine 10 mg
Number of subjects: 14
Study 2903762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine 20 mg
Number of subjects: 14
Study 2903762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine 10 mg (multiple dosing for 14 days)
Number of subjects: 14
Study 2903762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine 20 mg (multiple dosing for 14 days)
Number of subjects: 14
Study 2903762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine (both doses)
Number of subjects: 14
Study 2903762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30730813 — intervention group
Group type: EXPERIMENTAL
Intervention: EX + SIT (sitting 1 h, moderate-intensity walking 30 min, uninterrupted sitting 6.5 h)
Number of subjects: 12
Study 30730813 — intervention group
Group type: EXPERIMENTAL
Intervention: EX + BR (sitting 1 h, moderate-intensity walking 30 min, sitting 6.5 h with 3 min light-intensity walking every 30 min)
Number of subjects: 12
Study 30730813 — intervention group
Group type: COMPARATOR
Intervention: SIT (prolonged sitting 8 h, control)
Number of subjects: 12
Study 28806917 — intervention group
Group type: EXPERIMENTAL
Intervention: My Tools 4 Care (MT4C)
Number of subjects: 180
Study 28806917 — intervention group
Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 180
Study 25003426 — intervention group
Group type: EXPERIMENTAL
Intervention: TCL releasing only (Group 1)
Number of subjects: 113
Study 25003426 — intervention group
Group type: EXPERIMENTAL
Intervention: TCL and distal forearm fascia releasing (Group 2)
Number of subjects: 113
Study 23865657 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily calorie recommendations
Number of subjects: 1121
Study 23865657 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-meal calorie recommendations
Number of subjects: 1121
Study 23865657 — intervention group
Group type: COMPARATOR
Intervention: No calorie recommendations
Number of subjects: 1121
Study 21360507 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release sildenafil 200 mg once daily for 25 days
Number of subjects: 57
Study 21360507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 21360507 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release sildenafil
Number of subjects: 57
Study 21360507 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release sildenafil and Placebo
Number of subjects: 57
Study 19422140 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic) at 1000 microg/day
Number of subjects: 63
Study 19422140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16417639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping with dentures
Number of subjects: 48
Study 16417639 — intervention group
Group type: COMPARATOR
Intervention: Sleeping without dentures
Number of subjects: 48
Study 15246645 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (ILR) - Reveal Plus ILR
Number of subjects: 201
Study 15246645 — intervention group
Group type: COMPARATOR
Intervention: Conventional investigation
Number of subjects: 201
Study 12575565 — intervention group
Group type: EXPERIMENTAL
Intervention: Xianlong Capsule (XLC)
Number of subjects: 68
Study 12575565 — intervention group
Group type: COMPARATOR
Intervention: Hydergine
Number of subjects: 68
Study 9573428 — intervention group
Group type: EXPERIMENTAL
Intervention: Told-alcohol condition (alcohol-dependent subjects)
Number of subjects: 30
Study 9573428 — intervention group
Group type: EXPERIMENTAL
Intervention: Told-alcohol condition (moderately dependent alcoholics)
Number of subjects: 30
Study 9573428 — intervention group
Group type: EXPERIMENTAL
Intervention: Told-alcohol condition (severely dependent alcoholics)
Number of subjects: 30
Study 9573428 — intervention group
Group type: COMPARATOR
Intervention: Told-alcohol condition (social drinkers)
Number of subjects: 30
Study 9573428 — intervention group
Group type: EXPERIMENTAL
Intervention: Told-soft drinks condition (not specified for alcoholics)
Number of subjects: 30
Study 7838516 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day, then 100 mg for 6.8 days)
Number of subjects: 194
Study 7838516 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (100 mg twice a day for 8.0 days)
Number of subjects: 194
Study 3283356 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg IV-methylprednisolone
Number of subjects: 29
Study 3283356 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg IV-methylprednisolone
Number of subjects: 29
Study 3283356 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg IM-methylprednisolone
Number of subjects: 29
Study 31654276 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolife intervention (12 weeks' access to the Evolife website, face-to-face introductory session, and a pedometer)
Number of subjects: 60
Study 31654276 — intervention group
Group type: COMPARATOR
Intervention: NHS online health resources (control condition with face-to-face introductory session)
Number of subjects: 60
Study 28077584 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Number of subjects: 10245
Study 28077584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10245
Study 26018947 — intervention group
Group type: EXPERIMENTAL
Intervention: EA (Electroacupuncture)
Number of subjects: 60
Study 26018947 — intervention group
Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 60
Study 26018947 — intervention group
Group type: COMPARATOR
Intervention: Standard care (usual care with antiemetics)
Number of subjects: 60
Study 24554949 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 96
Study 24554949 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 96
Study 24554949 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 21851022 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lung maneuver
Number of subjects: 81
Study 21851022 — intervention group
Group type: COMPARATOR
Intervention: Standard respiratory support (control)
Number of subjects: 81
Study 19398602 — intervention group
Group type: EXPERIMENTAL
Intervention: LXR-623
Number of subjects: 0
Study 17201540 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude clarity
Number of subjects: 0
Study 17201540 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude correctness
Number of subjects: 0
Study 15134764 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly familiar symbols
Number of subjects: 0
Study 15134764 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately familiar symbols
Number of subjects: 0
Study 15134764 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly unfamiliar symbols
Number of subjects: 0
Study 11842449 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized psychocognitive educational intervention
Number of subjects: 60
Study 11842449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study 9219316 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg
Number of subjects: 9000
Study 9219316 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg and 15 mg
Number of subjects: 9000
Study 7932124 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1% (Voltaren) solution
Number of subjects: 65
Study 7932124 — intervention group
Group type: COMPARATOR
Intervention: Tears Naturale (control group)
Number of subjects: 65
Study 2905149 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40, 80 and 160 mg)
Number of subjects: 12
Study 2905149 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 and 100 mg)
Number of subjects: 12
Study 2905149 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (15 mg)
Number of subjects: 12
Study 26987871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (individualized training programmes aiming for ≥90 min of moderate-to-vigorous activity each week)
Number of subjects: 31
Study 26987871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 31
Study 26987871 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group, n=7)
Number of subjects: 31
Study 27404007 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional SMS campaign
Number of subjects: 2312
Study 27404007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored SMS campaign
Number of subjects: 2312
Study 27404007 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine SMS counseling)
Number of subjects: 2312
Study 24325147 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg simethicone suspension in 5 mL water
Number of subjects: 1849
Study 24325147 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg simethicone suspension in 100 mL water
Number of subjects: 1849
Study 24325147 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg simethicone suspension in 100 mL water containing 200 mg N-acetylcysteine
Number of subjects: 1849
Study 24325147 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 1849
Study 22732860 — intervention group
Group type: EXPERIMENTAL
Intervention: Popliteal block
Number of subjects: 51
Study 22732860 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GETA)
Number of subjects: 51
Study 19748613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton‐tipped applicator primed gauze pledgetting (CTGP)
Number of subjects: 240
Study 19748613 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic‐guided aerosolized spray (EGAS)
Number of subjects: 240
Study 18406179 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin alone (H)
Number of subjects: 2107
Study 18406179 — intervention group
Group type: COMPARATOR
Intervention: Heparin reversed with protamine (H+P)
Number of subjects: 2107
Study 16199404 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR training program (two 4-hr workshops, four individualized on-site consultations, three leadership sessions)
Number of subjects: 114
Study 16199404 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR training program
Number of subjects: 114
Study 12840647 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow weight training
Number of subjects: 38
Study 12840647 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive weight training
Number of subjects: 38
Study 12840647 — intervention group
Group type: COMPARATOR
Intervention: Control (usual training)
Number of subjects: 38
Study 10563141 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 90
Study 10563141 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 90
Study 10563141 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study 10186680 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician reminder letter combined with telephone counseling from a health educator
Number of subjects: 304
Study 10186680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention costs
Number of subjects: 304
Study 10186680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention process
Number of subjects: 304
Study 10186680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cost reduction strategies
Number of subjects: 304
Study 10186680 — intervention group
Group type: EXPERIMENTAL
Intervention: Women’s comfort level
Number of subjects: 304
Study 1493628 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar diathermy
Number of subjects: 150
Study 1493628 — intervention group
Group type: COMPARATOR
Intervention: Ligation for haemostasis
Number of subjects: 150
Study 1493628 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar diathermy and Ligation
Number of subjects: 150
Study 3887548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 27
Study 3887548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30501928 — intervention group
Group type: EXPERIMENTAL
Intervention: IOLMaster
Number of subjects: 61
Study 30501928 — intervention group
Group type: EXPERIMENTAL
Intervention: SlitLamp
Number of subjects: 61
Study 30501928 — intervention group
Group type: EXPERIMENTAL
Intervention: ImageJ
Number of subjects: 61
Study 30501928 — intervention group
Group type: COMPARATOR
Intervention: SlitLamp vs ImageJ
Number of subjects: 61
Study 29653686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase 20 mg/day
Number of subjects: 261
Study 29653686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase 40 mg/day
Number of subjects: 261
Study 29653686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase (varied doses from 5 mg/day to 60 mg/day)
Number of subjects: 261
Study 29653686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase treatment
Number of subjects: 261
Study 24861503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe-Simvastatin (E-S) 10/40 mg
Number of subjects: 128
Study 24861503 — intervention group
Group type: COMPARATOR
Intervention: High dose Rosuvastatin 20 mg
Number of subjects: 128
Study 21704482 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific total knee arthroplasty
Number of subjects: 50
Study 21704482 — intervention group
Group type: COMPARATOR
Intervention: Conventional unisex total knee arthroplasty
Number of subjects: 50
Study 21704482 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient subjective preferences
Number of subjects: 50
Study 21704482 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologic results
Number of subjects: 50
Study 20813979 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (0.21 O2 fraction, 98% arterial O2 saturation)
Number of subjects: 11
Study 20813979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypoxia (0.16 O2 fraction, 93% arterial O2 saturation)
Number of subjects: 11
Study 20813979 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (0.13 O2 fraction, 85% arterial O2 saturation)
Number of subjects: 11
Study 20813979 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoxia (0.10 O2 fraction, 74% arterial O2 saturation)
Number of subjects: 11
Study 16875813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) delivered by HFA‐227 metered dose inhaler (MDI) 400 microg bid
Number of subjects: 123
Study 16875813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) delivered by HFA‐227 metered dose inhaler (MDI) 800 microg bid
Number of subjects: 123
Study 16875813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 16875813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) in the open-label phase
Number of subjects: 123
Study 16875813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) treatment
Number of subjects: 123
Study 16261774 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 16261774 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60
Study 11884789 — intervention group
Group type: COMPARATOR
Intervention: 75 ml of contrast material (Ioversol 320) only (Group A)
Number of subjects: 125
Study 11884789 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 ml of contrast medium pushed with 6 ml saline (Group B)
Number of subjects: 125
Study 11884789 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 ml of contrast medium pushed with 12 ml saline (Group C)
Number of subjects: 125
Study 11884789 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 ml of contrast medium pushed with 25 ml saline (Group D)
Number of subjects: 125
Study 11884789 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 ml of contrast medium pushed with 50 ml saline (Group E)
Number of subjects: 125
Study 10567802 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication with posterior cruroplasty (n = 16)
Number of subjects: 31
Study 10567802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen cruroplasty with onlay of polytetrafluoroethylene (PTFE) mesh (n = 15)
Number of subjects: 31
Study 7916913 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (1 mg, intramuscularly)
Number of subjects: 6
Study 7916913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2515016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin (T)
Number of subjects: 200
Study 2515016 — intervention group
Group type: COMPARATOR
Intervention: Gold thiosulphate (GTS)
Number of subjects: 200
Study 30872104 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral viscous budesonide (OVB) 1 mg/4 mL twice daily
Number of subjects: 111
Study 30872104 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone MDI 880 μg twice daily
Number of subjects: 111
Study 28656805 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH), single dose, 10 mg
Number of subjects: 22
Study 28656805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28656805 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study 26463044 — intervention group
Group type: EXPERIMENTAL
Intervention: Information suggesting that other children had eaten a large amount of carrots
Number of subjects: 143
Study 26463044 — intervention group
Group type: COMPARATOR
Intervention: No carrots
Number of subjects: 143
Study 26463044 — intervention group
Group type: COMPARATOR
Intervention: Control information
Number of subjects: 143
Study 23323043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower kilovoltage potential (kVp) (A)
Number of subjects: 4500
Study 23323043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate kVp (B)
Number of subjects: 4500
Study 23323043 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher kVp (C)
Number of subjects: 4500
Study 23323043 — intervention group
Group type: COMPARATOR
Intervention: Fixed high kVp group (controls)
Number of subjects: 4500
Study 20851057 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (CCI)
Number of subjects: 362
Study 20851057 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 362
Study 18076218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily for 6 days and once on day 7
Number of subjects: 36
Study 18076218 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran etexilate with pantoprazole 40 mg twice daily starting 2 days prior to dabigatran administration
Number of subjects: 36
Study 16929431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gothenburg osseointegrated titanium (GOT) system
Number of subjects: 40
Study 16929431 — intervention group
Group type: COMPARATOR
Intervention: Cemented Spectron femoral component and cementless Trilogy cup
Number of subjects: 40
Study 14559386 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally administered allopregnanolone gel during the last 10 days of the second cycle (group 1)
Number of subjects: 13
Study 14559386 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally administered allopregnanolone gel during the last 10 days of each cycle (group 2)
Number of subjects: 13
Study 11136298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg once daily for 5 days
Number of subjects: 10
Study 11136298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8633255 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 176
Study 8633255 — intervention group
Group type: COMPARATOR
Intervention: Definitive radiotherapy (60 Gy)
Number of subjects: 176
Study 8633255 — intervention group
Group type: COMPARATOR
Intervention: Resection plus postoperative irradiation (45 Gy)
Number of subjects: 176
Study 8404160 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 41
Study 8404160 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 41
Study 3533126 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (84 mg total over 4 days, starting with 24 mg 2 hours after surgery)
Number of subjects: 24
Study 3533126 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1 g at 2, 6, and 9 hours after surgery, then 500 mg four times daily for the next 2 days)
Number of subjects: 24
Study 3533126 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 24
Study 30127197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectional matrix band system
Number of subjects: 1200
Study 30127197 — intervention group
Group type: COMPARATOR
Intervention: Circumferential matrix band system
Number of subjects: 1200
Study 25758633 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program (3-stage training plan)
Number of subjects: 80